PegIntron Increases Relapse-Free Survival In Stage III Melanoma, Schering Says
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. approval as adjuvant therapy for melanoma has been delayed by ODAC data requests, postponed meeting.
You may also be interested in...
ODAC To Assess Schering's PegIntron and GSK's Votrient In October
The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.
ODAC To Assess Schering's PegIntron and GSK's Votrient In October
The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.
Schering-Plough Lays Out Phase III Plan For HCV Therapy Boceprevir
Surprise move pre-dates final Phase II SPRINT-1 data, closes gap with Vertex’s telaprevir.